Treatment Algorithms for Early-Stage HR+ Breast Cancer

Opinion
Video

Virginia Kaklamani, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss treatment paradigms for patients with early-stage HR+ breast cancer, highlighting the differences in treatment for premenopausal and postmenopausal patients.

Recent Videos
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content
Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer, enhancing patient outcomes and safety.

3 Things You Should Know About Frontline TROP2-Targeting Antibody-Drug Conjugate/Immune Checkpoint Inhibitor Combinations to Treat Advanced Triple-Negative Breast Cancer

ONCOLOGY Staff
October 31st 2025
Article

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer, enhancing patient outcomes and safety.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Allireza Alloo, MD

An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer

Tim Cortese
October 27th 2025
Article

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.

Patient-Reported Outcomes Support Sacituzumab Govitecan Combo in TNBC

Kristie L. Kahl
October 23rd 2025
Article

Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.

Dato-DXd May Be Next SOC in First-Line TNBC

Dato-DXd May Be Next SOC in First-Line TNBC

Kristi Rosa
October 20th 2025
Article

Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.